Analyst Profile

Followed by 11 followers
.
Keyur Parekh

Keyur Parekh

Goldman Sachs
Wall Street Analyst
#2,379 out of 8,160 Wall Street Analysts
#5,173 out of 24,427 experts

Success Rate

55%
156 out of 285 transactions made a profit

Average Return

+2.70%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
Copying Keyur Parekh's trades since 2016 and holding each position for 1 Year would result in 54.74% of your transactions generating a profit, with an average return of 2.7% per rating.

Stock Rating Distribution

486Ratings
67.08% Buy
24.28% Sell
8.64% Hold
Distribution of Keyur Parekh's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United KingdomUK Market
United StatesUS Market

Best Rating

Stock:
Novo Nordisk A/S (UK)
(0QIU)
Rating:Buy
Date:May 05, 2021 - May 05, 2022
Return:+72.10%
The most profitable rating made by Keyur Parekh

Keyur Parekh's Stock Coverage

Company
Date
Position
Action
Price Target
No. of Ratings
Success Rate
Avg. Return
Bayer
Sep 14, 2016
Buy
Reiterated
1Ratings
100%
+28.40%
GlaxoSmithKline
Sep 19, 2016
Buy
Reiterated
2Ratings
0%
-3.10%
SHPG
Shire
Oct 11, 2016
Buy
Reiterated
4Ratings
33%
-11.43%
Roche Holding
Dec 20, 2016
Buy
Reiterated
1Ratings
100%
+11.80%
ZEAL
Zealand Pharma
Sep 27, 2017
Buy
Initiated
$26.00
(47.81% Upside)
1Ratings
0%
-12.60%
Galapagos
Aug 09, 2018
Hold
Downgraded
3Ratings
100%
+52.10%
Novo Nordisk
Oct 04, 2018
Buy
Reiterated
$450.00
(256.77% Upside)
5Ratings
80%
+28.92%
Sanofi-Aventis Sa
Mar 10, 2020
Buy
Upgraded
2Ratings
100%
+6.40%
Novartis
Apr 03, 2020
Buy
Reiterated
$116.00
(29.15% Upside)
2Ratings
100%
+11.75%
AstraZeneca
Mar 22, 2021
Sell
Reiterated
9Ratings
0%
-17.21%
List of latest recommendations made by Keyur Parekh. Click to expand and see Keyur Parekh's performance on a particular stock
Disclaimer: TipRanks collects analysts’ ratings and price targets by scanning publicly available reports on financial websites and by receiving reports from analysts, firms, or customers. The information and statistics displayed might not be accurate, complete, or up-to-date. The analyst ratings provided are the sole responsibility of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings, or opinions expressed.
Send Us Reports
If you receive reports that you think we are missing, we will thank you with a free Ultimate upgrade!
Learn More >